Patent AU-2012372140-B2 (AU)
Title: Uses of immunoconjugates targeting CD138
Inventor: SCHULZ GREGOR
IPC: A61K39/44
Filed: 2012-12-07
Granted: 2015-09-17
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2013/083817 Al 13 June 2013 (13.06.2013) W I PO I P CT (51) International Patent Classification: 53, 63225 Langen (DE). BERNOESTER, Katrin A61K 47/48 (2006.01) A61P 35/00 (2006.01) [DE/DE]; Obergasse 75, 65207 Wiesbaden (DE). (21) International Application Number: KOENIG, Martin [DE/DE]; Traunsteinerstrasse 14, PCT/EP2012/074867 65205 Wiesbaden (DE). (22) International Filing Date: (74) Agent: JEFFREY NICHOLAS DANIELS; Page White (2 Intenatona Fihn Date:2.20) & Farrer, Bedford House, John Street, London Greater 7 December 2012 (07.12.2012) London WC1N 2BF (GB). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (30) Priority Data: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 61/568,640 8 December 2011 (08.12.2011) US DO, DZ, EC, EE, EG, ES, Fl, GB, GD, GE, GH, GM, GT, 61/722,367 5 November 2012 (05.11.2012) US HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (71) Applicants (for all designated States except US): BI- KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, OTEST AG [DE/DE]; Landsteinerstrasse 5, 63303 Dreie- ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, ich (DE). IMMUNOGEN, INC. [US/US]; 830 Winter NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, Street, Waltham, Massachusetts 02451 (US). RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (72) Inventors; and ZM, ZW. (71) Applicants (for US only): SCHULZ, Gregor [DE/DE]; Rosenstrasse 13, 79224 Umkirch (DE). OSTERROTH, (84) Designated States (unless otherwise indicated, for every Frank [DE/DE]; Boellstrasse 24, 63128 Dietzenbach kind of regional protection available): ARIPO (BW, GH, (DE). HAEDER, Thomas [DE/DE]; Staffordstrasse 39a, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 63303 Dreieich (DE). BRUECHER, Christoph [DE/DE]; UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Unter den Tannen 3a, 65760 Eschborn (DE). NIEMANN, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Gabriele [D ] KraichgEE, ES, Fl, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, -aril [DE/DE], Kacgaustrasse 5, 75045 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Walzbachtal (DE). ENGLING, Andre [DE/DE]; Linden- MC, MK, MT, B, CF, C, PT, C, G, G, G, G, strasse 27a, 61352 Bad Homburg (DE). UHEREK, Chris- TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, toph [DE/DE]; Lachenwoerthweg 6, 63500 Seligenstadt (DE). DAELKEN, Benjamin [DE/DE]; Eleonore-Ster- Published: ling-Strasse 40, 60433 Frankfurt am Main (DE). - with international search report (Art. 21(3)) WARTENBERG-DEMAND, Andrea [DE/DE]; Alsfeld er Strasse 20-22, 34637 Schrecksbach (DE). ZUBER, - with sequence listing part of description (Rule 5.2(a)) Chantal [DE/DE]; Welserweg 9/1, 89077 Ulm (DE). GUTSCHER, Marcus [DE/DE]; Theodor-Heuss Strasse (54) Title: USES OF IMMUNOCONJUGATES TARGETING CD 138 0 (57) Abstract: Provided is a method for treating a disease associated with target cells expressing CD 138 comprising: administering to a subject, in particular a human subject, in need thereof an immunoconjugate comprising at least one engineered targeting anti body targeting CD138 expressing cells, and at least one effector molecule, wherein said engineered targeting antibody is functionally attached to said effector molecule to form said immunoconjugate, wherein preferably at least a part of the engineered targeting anti body confers lgG4 isotype properties, wherein the immunoconjugate is administered in a multiple dose regimen comprising at least two doses, wherein the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose f4 (AMTD) or a fraction of the AMTD and wherein said AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen and/or ex ceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a mul tiple single dose regimen within said active treatment cycle.